LOXL2 and myelofibrosis: Lysyl oxidase-like 2 inhibitors and the blocking antibody Simstuzimab are already in phase II clinical trials for fibrotic diseases, and some orally administered small inhibitors recently concluded Phase 1 and Phase 2a clinical trials in myelofibrosis patients intolerant or unresponsive to conventional approved treatments [45,46].